ReviewFrontiers in artificial intelligence2025
Deep learning for cardiovascular management: optimizing pathways and cost control under diagnosis-related group models.
Review in Frontiers in artificial intelligence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ultrasound in cardiovascular care: a perspective on preventive, diagnostic, and monitoring applications.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs) remain the leading causes of morbidity, mortality, and healthcare expenditures, presenting substantial challenges for hospitals operating under Diagnosis-Related Group (DRG) payment models. Recent advances in deep learning offer new strategies for optimizing CVD management to meet cost control objectives. This review synthesizes the roles of deep learning in CVD diagnosis, treatment planning, and prognostic modeling, emphasizing applications that reduce unnecessary diagnostic imaging, predict high-cost complications, and optimize the utilization of critical resources like ICU beds. By analyzing medical images, forecasting adverse events from patient data, and dynamically optimizing treatment plans, deep learning offers a data-driven strategy to manage high-cost procedures and prolonged hospital stays within DRG budgets. Deep learning offers the potential for earlier risk stratification and tailored interventions, helping mitigate the financial pressures associated with DRG reimbursements. Effective integration requires multidisciplinary collaboration, robust data governance, and transparent model design. Real-world evidence, drawn from retrospective studies and large clinical registries, highlights measurable improvements in cost control and patient outcomes; for instance, AI-optimized treatment strategies have been shown to reduce estimated mortality by 3.13%. However, challenges-such as data quality, regulatory compliance, ethical issues, and limited scalability-must be addressed to fully realize these benefits. Future research should focus on continuous model adaptation, multimodal data integration, equitable deployment, and standardized outcome monitoring to validate both clinical quality and financial return on investment under DRG metrics. By leveraging deep learning's predictive power within DRG frameworks, healthcare systems can advance toward a more sustainable model of high-quality, cost-effective CVD care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.